“Assay”的搜索结果，显示 121-130 项，共有 6059 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay results. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors ... assays and results from a ctDNA assay ...

3. 普通内科- 临床试验- 妙佑医疗国际

   The purose of this study is to develop assays to ... This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay ...

4. 心血管医学- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...

5. 心血管医学- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors ... assays and results from a ctDNA assay ...

7. 心血管医学- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...

8. 心血管医学- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...

9. 心血管医学- 临床试验- 妙佑医疗国际

   The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...

10. 心血管医学- 临床试验- 妙佑医疗国际

    Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...